Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Journal of Thoracic Oncology

Volumn 10, Issue 9, 2015, Pages 1285-1291

  Ten Haaf, Kevin ^a   De Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Lung cancer; Never smokers; Screening

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIMULATION; SMOKING; SMOKING CESSATION; SURVIVAL; UNITED STATES PREVENTIVE SERVICE TASK FORCE CRITERIA; EARLY CANCER DIAGNOSIS; LUNG NEOPLASMS; MASS SCREENING; RISK ASSESSMENT;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; RISK ASSESSMENT;

EID: 84940110021     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000593     Document Type: Article

References (49)

1. Koo LC, Ho JH, Worldwide epidemiological patterns of lung cancer in nonsmokers. Int J Epidemiol 1990 19 Suppl 1 S14 S23
2. Parkin DM, Bray F, Ferlay J, Pisani P, Global cancer statistics, 2002. CA Cancer J Clin 2005 55 74 108
3. Sun S, Schiller JH, Gazdar AF, Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007 7 778 790
4. Thun MJ, Henley SJ, Burns D, Jemal A, Shanks TG, Calle EE, Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 2006 98 691 699
5. Aberle DR, Adams AM, Berg CD, Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011 365 395 409
6. Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2014 160 330 338
7. Wood DE, Eapen GA, Ettinger DS, Lung cancer screening. J Natl Compr Canc Netw 2012 10 240 265
8. Smith RA, Manassaram-Baptiste D, Brooks D, Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2014 64 30 51
9. Detterbeck FC, Mazzone PJ, Naidich DP, Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. CHEST Journal 2013 143 e78S e92S
10. Sone S, Nakayama T, Honda T, Long-term follow-up study of a population-based 1996-1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography. Lung Cancer 2007 58 329 341
11. Sone S, Takashima S, Li F, Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998 351 1242 1245
12. Oken MM, Hocking WG, Kvale PA, PLCO Project Team Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011 306 1865 1873
13. Silvestri GA, Nietert PJ, Zoller J, Carter C, Bradford D, Attitudes towards screening for lung cancer among smokers and their non-smoking counterparts. Thorax 2007 62 126 130
14. McCarthy WJ, Meza R, Jeon J, Moolgavkar SH, Chapter 6: Lung cancer in never smokers: epidemiology and risk prediction models. Risk Anal 2012 32 Suppl 1) S69 S84
15. Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ, Lung cancer in never smokers-a review. Eur J Cancer 2012 48 1299 1311
16. Subramanian J, Govindan R, Lung cancer in never smokers: a review. J Clin Oncol 2007 25 561 570
17. Tammemagi CM, Pinsky PF, Caporaso NE, Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J Natl Cancer Inst 2011 103 1058 1068
18. Spitz MR, Hong WK, Amos CI, A risk model for prediction of lung cancer. J Natl Cancer Inst 2007 99 715 726
19. Raji OY, Duffy SW, Agbaje OF, Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med 2012 157 242 250
20. Tammemägi MC, Church TR, Hocking WG, Evaluation of the lung cancer risks at which to screen ever-and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med 2014 11 e1001764
21. El-Zein RA, Lopez MS, D'Amelio AM, The cytokinesis blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model. Cancer Epidemiol Biomarkers Prev 2014 23 2462 2470
22. Kovalchik SA, Tammemagi M, Berg CD, Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013 369 245 254
23. Tammemägi MC, Katki HA, Hocking WG, Selection criteria for lung-cancer screening. N Engl J Med 2013 368 728 736
24. Baldwin DR, Duffy SW, Wald NJ, Page R, Hansell DM, Field JK, UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax 2011 66 308 313
25. de Koning HJ, Meza R, Plevritis SK, Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med 2014 160 311 320
26. ten Haaf K, van Rosmalen J, de Koning HJ, Lung cancer detectability by test, histology, stage and gender: estimates from the NLST and the PLCO trials. Cancer Epidemiol Biomarkers Prev 2015 24 154 161
27. Meza R, ten Haaf K, Kong CY, Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer 2014 120 1713 1724
28. McMahon PM, Meza R, Plevritis SK, Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling. PLoS One 2014 9 e99978
29. Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA, Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control 2008 17 198 204
30. Haiman CA, Stram DO, Wilkens LR, Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006 354 333 342
31. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, National Cancer Institute of Canada Clinical Trials Group Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 353 123 132
32. Thatcher N, Chang A, Parikh P, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005 366 1527 1537
33. Kawaguchi T, Matsumura A, Fukai S, Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010 5 1001 1010
34. Meguid RA, Hooker CM, Harris J, Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers. Chest 2010 138 500 509
35. Subramanian J, Velcheti V, Gao F, Govindan R, Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC). J Thorac Oncol 2007 2 827 830
36. Toh CK, Gao F, Lim WT, Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006 24 2245 2251
37. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER∗Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2012 Sub (1973-2010 varying)-Linked To County Attributes-Total U.S., 1969-2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission. Accessed March 29, 2014.
38. Heidenreich WF, Luebeck EG, Moolgavkar SH, Some properties of the hazard function of the two-mutation clonal expansion model. Risk Anal 1997 17 391 399
39. Meza R, Hazelton WD, Colditz GA, Moolgavkar SH, Analysis of lung cancer incidence in the Nurses' Health and the Health Professionals' Follow-Up Studies using a multistage carcinogenesis model. Cancer Causes Control 2008 19 317 328
40. Hazelton WD, Clements MS, Moolgavkar SH, Multistage carcinogenesis and lung cancer mortality in three cohorts. Cancer Epidemiol Biomarkers Prev 2005 14 1171 1181
41. Thun MJ, Hannan LM, Adams-Campbell LL, Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 2008 5 e185
42. Jeon J, Meza R, Krapcho M, Clarke LD, Byrne J, Levy DT, Chapter 5: Actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation. Risk Anal 2012 32 Suppl 1 S51 S68
43. Rosenberg MA, Feuer EJ, Yu B, Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death. Risk Anal 2012 32 Suppl 1 S25 S38
44. Holford TR, Levy DT, McKay LA, Patterns of birth cohort-specific smoking histories, 1965-2009. Am J Prev Med 2014 46 e31 e37
45. Thun MJ, Carter BD, Feskanich D, 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013 368 351 364
46. Wakelee HA, Chang ET, Gomez SL, Lung cancer incidence in never smokers. J Clin Oncol 2007 25 472 478
47. Mandelblatt JS, Cronin KA, Bailey S, Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009 151 738 747
48. Brenner DR, Hung RJ, Tsao MS, Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. BMC Cancer 2010 10 285
49. McRonald FE, Yadegarfar G, Baldwin DR, The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev Res (Phila) 2014 7 362 371